Literature DB >> 1795044

Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin.

M J Evans1, R Suenaga, N I Abdou.   

Abstract

Pooled normal human IgG for therapeutic use, following depletion of anti-DNA, anti-Fc, and anti-F(ab')2 of normal IgG, expressed antiidiotypic activity against anti-DNA derived from lupus sera. The antiidiotype enriched by elution from anti-DNA affinity columns bound directly to anti-DNA IgG and inhibited the binding of lupus sera to DNA but did not bind to normal IgG or inhibit the binding of anti-tetanus toxoid to tetanus toxoid. Antiidiotypes in pooled normal sera may have a role in the clinical improvement seen in patients with autoimmune diseases receiving intravenous immune globulin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795044     DOI: 10.1007/BF00918187

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

1.  Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intravenous immunoglobulins.

Authors:  M D Kazatchkine; F Rossi; Y Sultan; U Nydegger
Journal:  Int Rev Immunol       Date:  1989       Impact factor: 5.311

Review 2.  Down regulation of Fc receptors by IVIgG.

Authors:  J W Mannhalter; M M Eibl
Journal:  Int Rev Immunol       Date:  1989       Impact factor: 5.311

3.  Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin.

Authors:  W A McGuire; H H Yang; E Bruno; J Brandt; R Briddell; T D Coates; R Hoffman
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

Review 4.  The idiotype-antiidiotype network in human autoimmunity.

Authors:  N I Abdou
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

5.  Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin.

Authors:  P Berchtold; G L Dale; P Tani; R McMillan
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

6.  Comparative study of idiotypes on monoclonal antibodies derived from patients with lupus and leprosy and from normal individuals.

Authors:  C G Mackworth-Young; E Cairns; J Sabbaga; H Massicotte; B Diamond; D A Bell; R S Schwartz
Journal:  J Autoimmun       Date:  1990-08       Impact factor: 7.094

7.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  P Gajdos; H Outin; D Elkharrat; D Brunel; P de Rohan-Chabot; J C Raphael; M Goulon; C Goulon-Goeau; E Morel
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

8.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

9.  Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins.

Authors:  K Akashi; K Nagasawa; T Mayumi; E Yokota; N Oochi; T Kusaba
Journal:  J Rheumatol       Date:  1990-03       Impact factor: 4.666

10.  IgG therapy in systemic lupus erythematosus--two case reports.

Authors:  G Gaedicke; W M Teller; E Kohne; R Dopfer; D Niethammer
Journal:  Blut       Date:  1984-06
View more
  13 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  Idiotypic mimicry of a cell surface DNA receptor: evidence for anti-DNA antibodies being a subset of anti-anti-DNA receptor antibodies.

Authors:  R M Bennett; K A Cornell; M J Merritt; A C Bakke; D Mourich; S H Hefeneider
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

Review 3.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

Review 4.  Toward molecular targeting with specific intravenous immunoglobulin preparation.

Authors:  Miri Blank; Israel Nur; Orgad Toub; Anabel Maor; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

6.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 7.  New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation.

Authors:  Y Shoenfeld; I Krause; M Blank
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

8.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

9.  Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; A S Payne; G J Anhalt; C Avivi; I Barshack; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

10.  Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations.

Authors:  F Silvestris; P Cafforio; F Dammacco
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.